克拉斯
医学
癌症
内科学
肿瘤科
肺癌
临床试验
突变
结直肠癌
生物
生物化学
基因
作者
Kathryn C. Arbour,Hira Rizvi,Andrew J. Plodkowski,Matthew D. Hellmann,Andrea Knežević,Glenn Heller,Helena A. Yu,Marc Ladanyi,Mark G. Kris,Maria E. Arcila,Charles M. Rudin,Piro Lito,Gregory J. Riely
标识
DOI:10.1158/1078-0432.ccr-20-4023
摘要
We provide outcome data for a large series of patients with KRAS G12C-mutant NSCLC with available therapies, demonstrating that responses and duration of benefit with available therapies are similar to those seen in patients with KRAS non-G12C mutations. Strategies to incorporate new targeted therapies into the current treatment paradigm will need to consider outcomes specific to patients harboring KRAS G12C mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI